Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 6, 2019, to report its financial and operating results for the second quarter ended June 30, 2019. This filing primarily serves to attach the press release containing these details, as the company is furnishing this information rather than formally filing it under certain SEC provisions. Investors should refer to the attached press release (Exhibit 99.1) for the specific financial figures and operational updates. The press release announced the company's performance for the quarter. While the 8-K itself does not contain the financial data, it directs investors to the attached exhibit for key metrics such as revenue, earnings per share, and updates on the company's product pipeline and commercial performance. This is a standard disclosure mechanism for companies to disseminate quarterly results.
Key Highlights
- 1Regeneron announced its Q2 2019 financial and operating results via a press release.
- 2The press release is furnished as Exhibit 99.1 to the 8-K filing.
- 3The 8-K filing itself does not contain detailed financial results, but refers investors to the press release.
- 4Information furnished is not considered 'filed' for Section 18 of the Securities Exchange Act of 1934.
- 5The filing occurred on August 6, 2019, reporting results for the quarter ended June 30, 2019.
- 6Investors need to consult Exhibit 99.1 for specific financial performance data and operational updates.